title: Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen.
abstract: OBJECTIVE
  Reduced-intensity conditioning regimens (RIC) and peripheral blood stem cells (PBSC) are increasingly used for allogeneic stem cell transplantation (allo-BMT). RIC has been shown to allow engraftment with minimal early transplant-related mortality (TRM). However, in the context of RIC, the use of bone marrow (BM) as stem cell source is still little evaluated.
  
  
  METHODS
  In this report, we analyzed the outcome of 32 high-risk patients with hematological malignancies who received an HLA-identical sibling allo-BMT after RIC including fludarabine, busulfan, and anti-thymocyte globulin (ATG).
  
  
  RESULTS
  Sustained neutrophil and platelet recovery occurred at a median of 13 days (range, 10-19) and 17 days (range, 0-45) respectively. Early and durable full donor chimerism could be established as soon as the first month after allo-BMT. Also, a sustained and early CD8(+) T-cell recovery was observed, but the CD4(+) T-cell compartment remained profoundly low. The cumulative incidences of grade II-IV acute GVHD and chronic GVHD were 26% (95% CI, 11-41%) and 31% (95% CI, 15-47%) respectively. The overall cumulative incidence of TRM was 28% (95% CI, 12-44%) occurring mainly in patients aged over 50. In this setting, GVHD showed a protective effect on disease progression or relapse with better progression-free survival for patients with GVHD as compared to patients without GVHD (p=0.03).
  
  
  CONCLUSIONS
  Collectively, these results confirm that the use of BM grafts for RIC is feasible with durable donor engraftment and no detrimental GVHD.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.forename: Béatrice
authors.initials: B
authors.lastname: Gaugler
authors.forename: Karin
authors.initials: K
authors.lastname: Bilger
authors.forename: Marie-Joelle
authors.initials: MJ
authors.lastname: Moziconnacci
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Patrick
authors.initials: P
authors.lastname: Ladaique
authors.forename: Christian
authors.initials: C
authors.lastname: Chabannon
authors.forename: Denis
authors.initials: D
authors.lastname: Reviron
authors.forename: Dominique
authors.initials: D
authors.lastname: Maraninchi
authors.forename: Jean-Albert
authors.initials: JA
authors.lastname: Gastaut
authors.forename: Daniel
authors.initials: D
authors.lastname: Olive
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D017708:Leukocyte Transfusion; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome